Fig. 3

Administration of iPSC-MSC-EXOs inhibited mitochondrial fragmentation and cardiomyocyte senescence in hearts of DIC mice. A Western blotting and quantitative measurement of the protein level of p16 and p21 in DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment or control mice. B Representative images of Troponin and p21 double staining in the heart of DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. C Quantitative measurement of Troponin⁺/p21⁺ double-positive cells in the heart of DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. D Representative TEM images showing the mitochondria in the heart of DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. E Quantitative measurement of mitochondrial fragmentation in the heart of DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. F Western blotting and quantitative measurement of the protein level of p-Drp1/Drp1, Mfn1 and Mfn2 in the heart of DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. Data are expressed as mean ± SD. n = 6 mice for each group, ***p < 0.001, ns = not significant